LGND Ligand Pharmaceuticals


Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

The 2021 Annual Meeting of the Stockholders of Ligand Pharmaceuticals Incorporated (the “Company”) was held on June 4, 2021 (the “Annual Meeting”). Set forth below are the final voting results for the actions taken by the stockholders at the Annual Meeting.

Proposal 1. The election of nine members of the Company’s board of directors for terms expiring at the 2022 annual meeting of stockholders. In accordance with the results below, each nominee was elected to serve as a director.

Votes ForVotes WithheldBroker Non-Votes
Jason M. Aryeh13,314,405396,1361,565,737
Sarah Boyce12,528,0151,280,5261,565,737
Todd C. Davis13,485,613322,9281,565,737
Nancy R. Gray13,415,408393,1331,565,737
John L. Higgins13,544,783263,7581,565,737
John W. Kozarich13,076,660731,8811,565,737
John L. LaMattina13,557,958250,5831,565,737
Sunil Patel13,473,085335,4561,565,737
Stephen L. Sabba13,331,554476,9871,565,737

Proposal 2. The ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. In accordance with the results below, the selection of Ernst & Young LLP was ratified.

Votes ForVotes AgainstAbstentionsBroker Non-Votes

Proposal 3. The approval of a non-binding advisory resolution regarding the compensation of the Company’s named executive officers. In accordance with the results below, the resolution was approved.

Votes ForVotes AgainstAbstentionsBroker Non-Votes